Login to Your Account

Neupogen Adcom 'Beta Test' for Radiation MCM Pathway

By Jennifer Boggs
Managing Editor

Wednesday, May 1, 2013
Biopharma firms that are working on medical countermeasures (MCMs) to combat radiation exposure are looking to a joint FDA advisory committee meeting Friday to help define a path for development of treatments for use in radiological or nuclear events.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription